Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Abstract excerpt

The gene encoding the receptor-tyrosine kinase RET was first discovered more than three decades ago, and activating RET rearrangements and mutations have since been identified as actionable drivers of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been observed in patients with...

Topics

Join the communities discussing this publication.

• Anaplastic Lymphoma Kinase
• Carcinogenesis
• Gene Rearrangement
• Molecular Targeted Therapy
• Protein-Tyrosine Kinases